Search | OpenScholar

Search results

1500 results found

ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Publication: Journal Article

Olanow, CW, O Rascol, RA Hauser, PD Feigin, J Jankovic, A Lang, W Langston, et al. 2009. “ADAGIO Study Investigators. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease.”. N Engl J Med.

Placebo response in Parkinson’s disease: Comparisons among 11 trials covering medical and surgical interventions

Publication: Journal Article

Goetz, CG, J Wuu, MP McDermott, CH Adler, S Fahn, CR Freed, RA Hauser, et al. 2008. “Placebo Response in Parkinson’s Disease: Comparisons Among 11 Trials Covering Medical and Surgical Interventions”. Mov Disord.

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results

Publication: Journal Article

Investigators, The NINDS NET-PD, and RA Hauser. 2008. “A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results”. Clin Neuropharmacol.

Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Movement Disorders 2004;19:426-432.

Publication: Journal Article

Waters, CH, KD Sethi, RA Hauser, E Molho, and JM Bertoni. 2004. “Zydis Selegiline Reduces Off Time in Parkinson’s Disease Patients With Motor Fluctuations: A 3-Month, Randomized, Placebo-Controlled Study. Movement Disorders 2004;19:426-432.”. Movement Disorders.

Levodopa/carbidopa/entacapone triple combination (Stalevo). Neurology 2004;62 (Suppl 1):S64-71.

Publication: Journal Article

Hauser, RA. 2004. “Levodopa/Carbidopa/Entacapone Triple Combination (Stalevo). Neurology 2004;62 (Suppl 1):S64-71.”. Neurology.

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson’s disease.

Publication: Journal Article

Hauser, RA, MP McDermott, S Messing, and Parkinson Study Group. 2006. “Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson’s Disease.”. Arch Neurol.

Nonmotor symptoms of Parkinson’s disease.

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, and RA Hauser. 2006. “Nonmotor Symptoms of Parkinson’s Disease.”. Expert Rev Neurother.

Identification of motor and nonmotor wearing-off in Parkinson’s disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20: 726-733.

Publication: Journal Article

Stacy, M, A Bowron, M Guttman, R Hauser, K Hughes, JP Larsen, P LeWitt, et al. 2005. “Identification of Motor and Nonmotor Wearing-off in Parkinson’s Disease: Comparison of a Patient Questionnaire versus a Clinician Assessment. Mov Disord 2005;20: 726-733.”. Mov Disord.

Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease.

Publication: Journal Article

Sullivan, KL, JK Staffetti, RA Hauser, PB Dunne, and TA Zesiewicz. 2006. “Tegaserod (Zelnorm) for the Treatment of Constipation in Parkinson’s Disease.”. Movement Disorders.

Clinical trials aimed at detecting neuroprotection in Parkinson’s disease.

Publication: Journal Article

Hauser, RA, and T Zesiewicz. 2006. “Clinical Trials Aimed at Detecting Neuroprotection in Parkinson’s Disease.”. Neurology.